candesartan has been researched along with Embryopathies in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Payen, V | 1 |
| Chemin, A | 1 |
| Jonville-Béra, AP | 1 |
| Saliba, E | 1 |
| Cantagrel, S | 1 |
1 review available for candesartan and Embryopathies
| Article | Year |
|---|---|
[Fetal toxicity of angiotensin-II receptor antagonists].
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Fe | 2006 |